PHM 431 Exam 3 Questions With Correct
Answers
amphetamine |- |CORRECT |ANSWER✔✔-not |a |substrate |for |MAO |but |it |is |for |VMAT
stored |in |vesicles |as |a |false |transmitter
false |transmitter |- |CORRECT |ANSWER✔✔-Released |as |a |transmitter |but |it |cannot |activate |
receptors
NE |B |receptor |- |CORRECT |ANSWER✔✔-stimulatory |G |protein |receptor, |activates |Gs, |which |
activates |adenylate |cyclase
Gs |- |CORRECT |ANSWER✔✔-activates |adenylate |cyclase
NE |a |receptor |- |CORRECT |ANSWER✔✔-produces |Gi, |which |inhibits |adenylate |cyclase
D1 |dopamine |receptir |- |CORRECT |ANSWER✔✔-activates |Gs |which |causes |an |excitatory |
response |by |activating |adenylate |cyclase
D2 |dopamine |receptor |- |CORRECT |ANSWER✔✔-activates |Gi |which |causes |an |inhibitory |
response
Pseudoephedrine |- |CORRECT |ANSWER✔✔-the |active |ingredient |in |sudafed |and |other |nasal |
decongestants. |it |is |the |stereoisomer |of |ephedrine
, Ephedrine/Pseudoephedrine |- |CORRECT |ANSWER✔✔-the |methyl |group |protects |from |
oxidation |and |makes |these |compounds |orally |active
not |metabolites |for |MAO |or |COMT |because |the |hydroxyl |groups |are |missing
Pseudoephrine |to |methamphetamine |- |CORRECT |ANSWER✔✔-need |LiAlH4 |or |Pd/C
requires |hydrogenation |of |OH |groups |and |dehalogenation
euphoric |effects |of |amphetamine |- |CORRECT |ANSWER✔✔-mediated |via |activation |of |the |
mesolimbic |dopamine |system. |Causes |dopamine |release |in |the |nucleus |accumbens
drug |wanting |- |CORRECT |ANSWER✔✔-correlated |with |personality |traits |of |exploratory |
excitability |and |novelty |seeking
amphetamine |and |satiety |- |CORRECT |ANSWER✔✔-causes |CART |peptides |to |be |induced, |CART |
peptides |inhibit |feeding |behavior |caused |by |neuropeptide |Y
increase |in |NPY |- |CORRECT |ANSWER✔✔-increase |in |feeding
CART |peptides |- |CORRECT |ANSWER✔✔-found |in |the |mesolimbic |dopamine |system |and |the |
hypothalamus
contribute |to |the |appetite |suppressing |effects |of |amphetamine
5q13-14 |locus |- |CORRECT |ANSWER✔✔-a |site |that |has |been |associated |with |susceptibility |to |
obesity
ritalin |- |CORRECT |ANSWER✔✔-large |bulky |substituents |make |it |orally |active
increases |activity |in |ventral |tegmental |area
increases |dopamine |release |in |frontal |cortex |and |caudate |putamen
Answers
amphetamine |- |CORRECT |ANSWER✔✔-not |a |substrate |for |MAO |but |it |is |for |VMAT
stored |in |vesicles |as |a |false |transmitter
false |transmitter |- |CORRECT |ANSWER✔✔-Released |as |a |transmitter |but |it |cannot |activate |
receptors
NE |B |receptor |- |CORRECT |ANSWER✔✔-stimulatory |G |protein |receptor, |activates |Gs, |which |
activates |adenylate |cyclase
Gs |- |CORRECT |ANSWER✔✔-activates |adenylate |cyclase
NE |a |receptor |- |CORRECT |ANSWER✔✔-produces |Gi, |which |inhibits |adenylate |cyclase
D1 |dopamine |receptir |- |CORRECT |ANSWER✔✔-activates |Gs |which |causes |an |excitatory |
response |by |activating |adenylate |cyclase
D2 |dopamine |receptor |- |CORRECT |ANSWER✔✔-activates |Gi |which |causes |an |inhibitory |
response
Pseudoephedrine |- |CORRECT |ANSWER✔✔-the |active |ingredient |in |sudafed |and |other |nasal |
decongestants. |it |is |the |stereoisomer |of |ephedrine
, Ephedrine/Pseudoephedrine |- |CORRECT |ANSWER✔✔-the |methyl |group |protects |from |
oxidation |and |makes |these |compounds |orally |active
not |metabolites |for |MAO |or |COMT |because |the |hydroxyl |groups |are |missing
Pseudoephrine |to |methamphetamine |- |CORRECT |ANSWER✔✔-need |LiAlH4 |or |Pd/C
requires |hydrogenation |of |OH |groups |and |dehalogenation
euphoric |effects |of |amphetamine |- |CORRECT |ANSWER✔✔-mediated |via |activation |of |the |
mesolimbic |dopamine |system. |Causes |dopamine |release |in |the |nucleus |accumbens
drug |wanting |- |CORRECT |ANSWER✔✔-correlated |with |personality |traits |of |exploratory |
excitability |and |novelty |seeking
amphetamine |and |satiety |- |CORRECT |ANSWER✔✔-causes |CART |peptides |to |be |induced, |CART |
peptides |inhibit |feeding |behavior |caused |by |neuropeptide |Y
increase |in |NPY |- |CORRECT |ANSWER✔✔-increase |in |feeding
CART |peptides |- |CORRECT |ANSWER✔✔-found |in |the |mesolimbic |dopamine |system |and |the |
hypothalamus
contribute |to |the |appetite |suppressing |effects |of |amphetamine
5q13-14 |locus |- |CORRECT |ANSWER✔✔-a |site |that |has |been |associated |with |susceptibility |to |
obesity
ritalin |- |CORRECT |ANSWER✔✔-large |bulky |substituents |make |it |orally |active
increases |activity |in |ventral |tegmental |area
increases |dopamine |release |in |frontal |cortex |and |caudate |putamen
